Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies

International Journal of Antimicrobial Agents

Volumn 32, Issue 6, 2008, Pages 511-514

  Johnson, Elizabeth ^a   Espinel Ingroff, Ana ^b   Szekely, Adrien ^a   Hockey, Hans ^c   Troke, Peter ^c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NONE   (United Kingdom)

Author keywords

Candida; Clinical outcome; Cryptococcus; MIC; Trichosporon

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; GEOTRICHUM CANDIDUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RHODOTORULA; SACCHAROMYCES CEREVISIAE; TRICHOSPORON;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CLINICAL TRIALS, PHASE III AS TOPIC; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MYCOSES; PYRIMIDINES; TRIAZOLES; YEASTS;

EID: 55249098598     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.05.023     Document Type: Article

References (31)

1. Espinel-Ingroff A., Boyle K., and Sheehan D.J. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150 (2001) 101-115
2. Pfaller M.A., Diekema D.J., Jones R.N., Messer S.A., and Hollis R.J. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program 1997 to 2000. J Clin Microbiol 40 (2002) 852-856
3. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J., and Jones R.N. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 41 (2003) 78-83
4. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J., and Jones R.N. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis 48 (2004) 101-105
5. Pfaller M.A., Messer S.A., Boyken L., Hollis R.J., Rice C., and Teudolkar S. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 48 (2004) 201-205
6. Pfaller M.A., Diekema D.J., Rinaldi M.G., Barnes R., Hu B., Veselov A.V., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 43 (2005) 5848-5859
7. Pfaller M.A., Diekema D.J., Rex R.H., Espinel-Ingroff A., Johnson E.M., Andes D., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 44 (2006) 819-826
8. Marco F., Almela M., Jurado A., Jurado A., Mensa J., de la Bellacasa J.P., et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis 46 (2003) 259-264
9. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
10. Marangon F.B., Miller D., Giaconi J., and Alfonso E.C. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 137 (2004) 820-825
11. Yang Y.L., Cheng H.H., and Lo H.J. In vitro activity of voriconazole against Candida species isolated in Taiwan. Int J Antimicrob Agents 24 (2004) 294-296
12. Morace G., and Polonelli L. Voriconazole activity against clinical yeast isolates: a multicentre Italian study. Int J Antimicrob Agents 26 (2005) 247-253
13. Munoz P., Sánchez-Somolinos M., Alcalá L., Rodriguez-Creixems M., Pelaez T., and Bouza E. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 55 (2005) 188-193
14. Peman J., Jarque I., Bosch M., Canton E., Salavert M., de Llanos R., et al. Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns. J Clin Microbiol 44 (2006) 1912-1914
15. Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C., Hare R., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important moulds and yeasts. Antimicrob Agents Chemother 50 (2006) 2009-2015
16. Hegener-P, Troke P.F., Fätkenhauer G., Diehl V., and Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12 (1998) 2227-2228
17. Ally R., Schurmann D., Kreisel W., Carosi C., Aguirrebengoa G., Dupont B., et al. A randomized, double-blind, double-dummy, multicentre trial of voriconazole and fluconazole in the treatment of oesophageal candidiasis in immunocompromised patients. Clin Infect Dis 33 (2001) 1447-1454
18. Perfect J.R., Marr K., Walsh T.J., Greenberg R.N., Dupont B., de la Torre-Cisneros J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 (2003) 1122-1131
19. Mohammedi I., Thiebaut A., Piens M.A., Arguad L., Martin O., and Robert D. Emergence of Candida albicans fungemia during voriconazole therapy. J Infect 51 (2005) e83-e84
20. Muldrew K.M., Maples H.M., Stowe C.D., and Jacobs R.F. Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy 25 (2005) 893-898
21. Panackal A.A., Gribskov J.L., Staab J.F., Kirby K.A., Rinaldi M., and Marr K.A. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 44 (2006) 1740-1743
22. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. 2nd ed. Approved standard. M27-A2. Villanova, PA: CLSI; 2002.
23. Ruhnke M., Schmidt-Westhausen A., and Trautmann M. In vitro activities of voriconazole (UK-109 496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41 (1997) 575-577
24. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 (2005) 1435-1442
25. Rex J.H., and Pfaller M.A. Has antifungal susceptibility testing come of age?. Clin Infect Dis 35 (2002) 982-989
26. Muller F.M., Weig M., Peter J., and Walsh T.J. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 46 (2000) 338-340
27. Sanguinetti M., Posteraro B., Fiori B., Ranno S., Torelli R., and Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 49 (2005) 668-679
28. Pfaller M.A., Messer S.A., Boyken L., Newell V.A., Meis J.F., Gould I.M., et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J Clin Microbiol 45 (2007) 70-75
29. Pemán J., Cantón E., Calabuig E., Bosch M., Valenti A., Viudes A., et al. In vitro activity of voriconazole against yeast and algae isolates according to new resistance pattern cut-off points. Rev Esp Quimioter 19 (2006) 21-33 [in Spanish]
30. Favel A., Michel-Nguyen A., Peyron F., Martin C., Thomachot L., Datry A., et al. Colony morphology switching of Candida lusitaniae and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature. Diagn Microbiol Infect Dis 47 (2003) 331-339
31. Eloy O., Blanc V., Pina P., Gaudart A., Bresolle M.L., Plainvert C., et al. Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004. Pathol Biol (Paris) 54 (2006) 523-530 [in French]